First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.

Authors

J. A. Sosman

Vanderbilt University Medical Center, Nashville, TN

J. A. Sosman , A. A. Adjei , P. LoRusso , S. A. Michael , G. K. Dy , A. Bowditch , B. Chmielowski , S. Lee , R. M. Walker , S. Faucette , E. S. Izmailova , V. Bozon , A. Ribas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.

First Author: Alex A. Adjei

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.

First Author: Filip Janku

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with patients with advanced differentiated thyroid cancer.

First Author: Shabina Roohi Ahmed

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.

First Author: J. Thaddeus Thaddeus Beck